A Small-Animal Pharmacokinetic/Pharmacodynamic PET Study of Central Serotonin 1A Receptor Occupancy by a Potential Therapeutic Agent for Overactive Bladder

PLoS ONE

Volumn 8, Issue 9, 2013, Pages

  Nakatani, Yosuke ^a,b,c   Suzuki, Michiyuki ^a,b   Tokunaga, Masaki ^b   Maeda, Jun ^b   Sakai, Miyuki ^a   Ishihara, Hiroki ^a   Yoshinaga, Takashi ^a   Takenaka, Osamu ^a   Zhang, Ming Rong ^b,c   Suhara, Tetsuya ^b,c   Higuchi, Makoto ^b,c  

^a EISAI CO LTD   (Japan)

^b NATIONAL INSTITUTE OF RADIOLOGICAL SCIENCES   (Japan)

^c TOHOKU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

E 2110; N [2 [4 (2 METHOXYPHENYL) 1 PIPERAZINYL]ETHYL] N (2 PYRIDYL)CYCLOHEXANECARBOXAMIDE; SEROTONIN 1A AGONIST; SEROTONIN 1A RECEPTOR; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; AREA UNDER THE CURVE; ARTICLE; BINDING AFFINITY; COMPARTMENT MODEL; CONTROLLED STUDY; DOSE RESPONSE; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG ELIMINATION; DRUG HALF LIFE; DRUG RECEPTOR BINDING; DRUG STRUCTURE; FEMALE; HIPPOCAMPUS; IN VIVO STUDY; MALE; MAXIMUM PLASMA CONCENTRATION; MICTURITION; NONHUMAN; OVERACTIVE BLADDER; POLLAKISURIA; POSITRON EMISSION TOMOGRAPHY; PROTEIN BINDING; QUANTITATIVE ANALYSIS; RAT; TIME TO MAXIMUM PLASMA CONCENTRATION;

8-HYDROXY-2-(DI-N-PROPYLAMINO)TETRALIN; ADMINISTRATION, ORAL; ANIMALS; COMPUTER SIMULATION; HIPPOCAMPUS; MICROSOMES; PIPERIDINES; POSITRON-EMISSION TOMOGRAPHY; PROTEIN BINDING; RATS; RATS, SPRAGUE-DAWLEY; RECEPTOR, SEROTONIN, 5-HT1A; REFLEX; SUPERIOR COLLICULI; TIME FACTORS; URINARY BLADDER, OVERACTIVE; URINATION;

EID: 84884509550     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0075040     Document Type: Article

References (23)

1. Abrams P, Cardozo L, Fall M, Griffiths D, Rosier P, et al. (2002) The standardisation of terminology of lower urinary tract function: report from the standardisation sub-committee of the International Continence Society. Neurourol Urodyn 21: 167-178. doi:10.1002/nau.10052. PubMed: 11857671.
2. Chapple C, Khullar V, Gabriel Z, Dooley JA, (2005) The effects of antimuscarinic treatments in overactive bladder: A systematic review and meta-analysis. Eur Urol 48: 5-26. doi:10.1016/j.eururo.2005.02.024. PubMed: 15885877.
3. Kershen RT, Hsieh M, (2004) Preview of new drugs for overactive bladder and incontinence: darifenacin, solifenacin, trospium, and duloxetine. Curr Urol Rep 5: 359-367. doi:10.1007/s11934-004-0083-x. PubMed: 15461912.
4. Scheife R, Takeda M, (2005) Central nervous system safety of anticholinergic drugs for the treatment of overactive bladder in the elderly. Clin Ther 27: 144-153. doi:10.1016/j.clinthera.2005.02.014. PubMed: 15811477.
5. Cheng CL, de Groat WC, (2010) Role of 5-HT1A receptors in control of lower urinary tract function in anesthetized rats. Am J Physiol Renal Physiol 298: F771-F778. PubMed: 20042459.
6. Abanades S, van der Aart J, Barletta JA, Marzano C, Searle GE, et al. (2011) Prediction of repeat-dose occupancy from single-dose data: characterisation of the relationship between plasma pharmacokinetics and brain target occupancy. J Cereb Blood Flow Metab 31: 944-952. doi:10.1038/jcbfm.2010.175. PubMed: 20940733.
7. McCarron JA, Turton DR, Pike VW, Poole KG, (1996) Remotely-controlled production of the 5-HT1A radioligand, [carbonyl-11C]WAY-100635, via 11C-carboxylation of an immobilized Grignard reagent. J Label Compd Radiopharm 38: 941-953. doi:10.1002/(SICI)1099-1344(199610)38:10.
8. Tai YC, Ruangma A, Rowland D, Siegel S, Newport DF, Chow PL, et al. (2005) Performance evaluation of the microPET focus: a third-generation microPET scanner dedicated to animal imaging. J Nucl Med 46: 455-463. PubMed: 15750159.
9. Lammertsma AA, Hume SP, (1996) Simplified reference tissue model for PET receptor studies. Neuroimage 4: 153-158. doi:10.1006/nimg.1996.0066. PubMed: 9345505.
10. Andrée B, Hedman A, Thorberg SO, Nilsson D, Halldin C, et al. (2003) Positron emission tomographic analysis of dose-dependent NAD-299 binding to 5-hydroxytryptamine-1A receptors in the human brain. Psychopharmacology (Berl) 167: 37-45. PubMed: 12632244.
11. Rabiner EA, Wilkins MR, Turkheimer F, Gunn RN, Udo de Haes J, et al. (2002) 5-Hydroxytryptamine1A receptor occupancy by novel full antagonist 2-[4-[4-(7-chloro-2,3-dihydro-1,4-benzdioxyn-5-yl)-1-piperazinyl]butyl]-1,2-benzisothiazol-3-(2H)-one-1,1-dioxide: A[11C][O-methyl-3H]-N-(2-(4-(2-methoxyphenyl)-1-piperazinyl)ethyl)-N-(2-pyridinyl)cyclohexanecarboxamide trihydrochloride (WAY-100635) positron emission tomography study in humans. J Pharmacol Exp Ther 301: 1144-1150. doi:10.1124/jpet.301.3.1144. PubMed: 12023549.
12. Raje S, Patat AA, Parks V, Schechter L, Plotka A, et al. (2008) A positron emission tomography study to assess binding of lecozotan, a novel 5-hydroxytryptamine-1A silent antagonist, to brain 5-HT1A receptors in healthy young and elderly subjects, and in patients with Alzheimer's disease. Clin Pharmacol Ther 83: 86-96. doi:10.1038/sj.clpt.6100232. PubMed: 17507923.
13. Sheiner LB, Stanski DR, Voseh S, Miller RD, Ham J, (1979) Simultaneous modelling of pharmacokinetics and pharmacodynamics: Application to dtubocurarine. Clin Pharmacol Ther 40: 86-93.
14. Pehrson R, Ojteg G, Ishizuka O, Andersson KE, (2002) Effects of NAD-299, a new, highly selective 5-HT1A receptor antagonist, on bladder function in rats. Naunyn Schmiedebergs Arch Pharmacol 366: 528-536. doi:10.1007/s00210-002-0650-y. PubMed: 12444493.
15. Saijo T, Maeda J, Okauchi T, Maeda J, Morio Y, et al. (2012) Presynaptic selectivity of a ligand for serotonin 1A receptors revealed by in vivo PET assays of rat brain. PLOS ONE 7: e42589. doi:10.1371/journal.pone.0042589. PubMed: 22880045.
16. Kapur S, Seeman P, (2000) Antipsychotic agents differ in how fast they come off the dopamine D2 receptors. Implications for atypical antipsychotic action. J Psychiatry Neurosci 25: 161-166. PubMed: 10740989.
17. Kato R, Yamazoe Y, (1992) Sex-specific cytochrome P450 as a cause of sex- and species-related differences in drug toxicity. Toxicol Lett 64-65Spec No: 661-667 doi:10.1016/0378-4274(92)90245-F. PubMed: 1471220.
18. Chovan JP, Ring SC, Yu E, Baldino JP, (2007) Cytochrome P450 probe substrate metabolism kinetics in Sprague Dawley rats. Xenobiotica 37: 459-473. doi:10.1080/00498250701245250. PubMed: 17523050.
19. Lecci A, Giuliani S, Santicioli P, Maggi CA, (1992) Involvement of 5-hydroxytryptamine1A receptors in the modulation of micturition reflexes in the anesthetized rat. J Pharmacol Exp Ther 262: 181-189. PubMed: 1352548.
20. Leonardi A, Testa R, (1997) Use of 5-HT1A receptor antagonists for the treatment of urinary incontinence. Application WO 9731637-A1.
21. Ramage AG, (2006) The role of central 5-hydroxytryptamine (5-HT, serotonin) receptors in the control of micturition. Br J Pharmacol 147 (Suppl 2):: S120-S131. doi:10.1038/sj.bjp.0706504. PubMed: 16465176.
22. Testa R, Guarneri L, Poggesi E, Angelico P, Velasco C, et al. (1999) Effect of several 5-hydroxytryptamine(1A) receptor ligands on the micturition reflex in rats: comparison with WAY 100635. J Pharmacol Exp Ther 290: 1258-1269. PubMed: 10454502.
23. de Groat WC, (2006) Integrative control of the lower urinary tract: preclinical perspective. Br J Pharmacol 147 (Suppl 2):: S25-S40. doi:10.1038/sj.bjp.0706604. PubMed: 16465182.